.png)
.png)
TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
Copyright © 2024 buzzstream. All Rights Reserved
Copyright © 2024 BuzzStream. All Rights Reserved.
All content on this website, including but not limited to text, images, graphics, logos, articles, and other materials, is the property of BuzzStream and is protected by international copyright laws. No part of this content may be reproduced, distributed, transmitted, displayed, published, or broadcast without BuzzStream's prior written permission. Unauthorized use of the content is strictly prohibited and may result in legal action.
For inquiries regarding the use or licensing of content, please contact us at 1-832-482-2215.
Feel free to customize it further if needed!
